MAPK3 and melanoma: In this respect, ATOX1 is critical for the activation of the MEK-ERK signaling pathway in BRAFV600E-mutated melanomas, as the pharmacological inhibition of ATOX1 by DC_AC50 decreases the phosphorylation of ERK1/2 and reduces the growth of BRAF-mutated melanoma cells [40].